ttorney Docket No.: 6246.200-US

PRECEIVED

MAR PATENT 2003

TECH CENTER 1600/2900

— IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Application No.: 10/090,011

Group Art Unit: 1653

Filed: February 26, 2002 Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

MAR 0 6 2003

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed. The reference is as follows:

> 1. WO 99/35245

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

The supplemental information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,


Date: March 3, 2003

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800

23650

PATENT TRADEMARK OFFICE

MAR 0 6 2003 Attorney Docket No.: 6246.200-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Serial No.: 10/090,011

Group Art Unit: 1653

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Supplemental Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of Reference

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on March 3, 2003

Rashida Haji

(name of person mailing paper)

(signature of person mailing paper)

						She	et 1 of 1
PO 1 PTO 1449 (Rev. 2-32)	U.S. DEPAR PATENT AN	TMENT OF COMMERCE	Atty. Docket No. 6246.200-US		Serial No. 10/090,011		
a	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant P. Serup et al				
R O 6 2003 R			Filing Date February 26, 2002		Group 1653		
A LATE		U.S. PATE	ENT DOCUMENTS		r <del> </del>		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	PRIATE
					D		
					8 11	FUEIN	VED
					MA TECH CE	R 1 0 20	100
					TENLAS	20	103
					TECH CE	ITER 160	10/20nn
							<del>"/~~~</del>
		FOREIGN PA	ATENT DOCUMENTS		<u> </u>		
	DOCUMENT		112111200001121112			TRANSLATION	
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 99 35245	7/15/99	PCT			х	
			A di Milla Data Ba	The second Pages F	40.)	·	
	OTHER	DOCUMENTS (Includin	g Author, Title, Date, re	rtment rages, E	(c.)		
				· · · · · · · · · · · · · · · · · · ·			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

DATE CONSIDERED